Change search
ReferencesLink to record
Permanent link

Direct link
Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor
KTH, School of Biotechnology (BIO), Molecular Biotechnology.
KTH, School of Biotechnology (BIO), Molecular Biotechnology.ORCID iD: 0000-0001-7034-0850
KTH, School of Biotechnology (BIO), Molecular Biotechnology.
Show others and affiliations
2010 (English)In: Biotechnology and applied biochemistry, ISSN 0885-4513, E-ISSN 1470-8744, Vol. 55, 99-109 p.Article in journal (Refereed) Published
Abstract [en]

Affibody molecules binding to the site of hormone interaction in IGF-IR (insulin-like growth factor-I receptor) were successfully selected by phage-display technology employing a competitive-elution strategy during biopanning, whereby release of receptor-bound phagemids was accomplished by competition with IGFI (insulin-like growth factor-I). In non-competitive selections, the elution of receptor-bound phagemids was performed by imidazole or low-pH incubation, which also resulted in the isolation of affibody molecules that could bind to the receptor. An ELISA-based assay showed that the affibody molecules generated by IGF-I competition during elution, in addition to affibody molecules generated in the noncompetitive selections, could compete with IGF-I for binding to the receptor. The affinities of the isolated variants to IGF-IR-overexpressing MCF-7 cells were determined and ranged from high nanomolar to 2.3 nM. The most promising variant, Z(4;40), was shown to recognize IGF- IR efficiently in several different contexts: in analyses based on flow cytometry, fluorescence microscopy and receptor pull-down from cell extracts. In addition, when Z, was added to the medium of MCF-7 cells that were dependent on IGF-I for efficient growth, it was found to have a dose-dependent growth-inhibitory effect on the cells. Applications of affibody-based reagents for quantitative and qualitative analyses of IGF- I R status, as well as applications of affibody-based reagents for therapy, are discussed.

Place, publisher, year, edition, pages
2010. Vol. 55, 99-109 p.
Keyword [en]
affibody molecule, competitive elution, insulin-like growth factor-1, receptor (IGF-IR), phage display, human-breast-cancer, monoclonal-antibody, carcinoma cells, proteins, domain, expression, libraries, scaffold
National Category
Industrial Biotechnology
URN: urn:nbn:se:kth:diva-19387DOI: 10.1042/ba20090226ISI: 000276539400005ScopusID: 2-s2.0-77954828431OAI: diva2:337434
Swedish Research Council, 621-20055134
QC 20100525Available from: 2010-08-05 Created: 2010-08-05 Last updated: 2011-01-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Lundberg, EmmaVernet, ErikGräslund, Torbjörn
By organisation
Molecular Biotechnology
In the same journal
Biotechnology and applied biochemistry
Industrial Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link